Browsing "1. Journal Papers" by Author : 4740

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 12 to 71 of 96

This table browses all dspace content
Issue DateTitleJournal Title
2018Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical PracticeJOURNAL OF THORACIC ONCOLOGY
2018Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survivalLUNG CANCER
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2023Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments CANCERS
2023Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea Cancer Treatment and Research Communications
2009Clinical value of ezrin expression in primary osteosarcoma CANCER RESEARCH AND TREATMENT
2017Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaANNALS OF ONCOLOGY
2020Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2019Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2017Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization ONCOTARGET
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2017Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis ONCOTARGET
2022Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma CLINICAL AND TRANSLATIONAL MEDICINE
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2009Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. CANCER RESEARCH AND TREATMENT
2021Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2019Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapyLUNG CANCER
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2018Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neckHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
2018Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.CANCER RESEARCH
2018ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinomaONCOGENE
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationLUNG CANCER
2021Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy CANCERS
2020Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerEXPERIMENTAL AND MOLECULAR MEDICINE
2019High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma SCIENTIFIC REPORTS
2019Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerAnnals of Oncology
2020Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives IMMUNE NETWORK
2019Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2019Incidence, inhospital mortality, and readmission among patients with alcoholic hepatitis in Korea: A nationwide studyGastroenterology & Hepatology
2022Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity FRONTIERS IN ONCOLOGY
2019Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinomaLUNG CANCER
2023Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerNATURE CANCER
2021Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients SCIENTIFIC REPORTS
2019Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyLANCET ONCOLOGY
2023Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyLUNG CANCER
2022Lazertinib: on the Way to Its Throne YONSEI MEDICAL JOURNAL
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2019Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing PLOS ONE
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2020Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response BRITISH JOURNAL OF CANCER
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2019Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate PLOS ONE
2021Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents KIDNEY RESEARCH AND CLINICAL PRACTICE
2010Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCANCER CHEMOTHERAPY AND PHARMACOLOGY
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma SCIENTIFIC REPORTS
2019Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma SCIENTIFIC REPORTS
2016PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients SCIENTIFIC REPORTS
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2023Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH TrialJOURNAL OF CLINICAL ONCOLOGY
2020Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCANCER
2014Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneCANCER CHEMOTHERAPY AND PHARMACOLOGY
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2023Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies CANCERS
2017Povidone-iodine for the management of oral mucositis during cancer therapy Oncology Reviews
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCCLINICAL CANCER RESEARCH
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2019Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitorsCancer Chemotherapy and Pharmacology
2022Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor YONSEI MEDICAL JOURNAL
12

Browse

Links